Researchers have successfully tested a drug in the laboratory that can kill the deadly Corvid-19 pathogen in a few hours.
Researchers have discovered a drug that can kill the causative agent of Covid-19 in just 48 hours. Previous laboratory tests have proven exactly that, now tests on humans are pending to determine the effect of the potential Coronavirus vaccine to prove.
Coronavirus vaccine: Not the only one in the works
There are currently over 20 coronavirus vaccines in development worldwide. One of these antidotes for Covid-19 has even progressed so far that the first volunteers are using the new drug in test series. Nevertheless, it can still take months before a finished product can be passed on to the population.
A potential coronavirus vaccine newly identified by Australian researchers could give rise to particularly great hope. The active ingredient “ivermectin” has not yet been administered to a Covid 19 patient, but laboratory analyzes have shown that the agent can eliminate any traces of the coronavirus in just two days.
New coronavirus vaccine thanks to old anti-parasite agent
“Ivermectin” is not a completely new drug. In fact, it is an active ingredient that was originally developed against parasites in the 1970s. Today, the potential coronavirus vaccine is a widely used and safe agent that is used against HIV infections, dengue fever and the Zika virus, among other things, as BGR reports.
“We found that even a simple dose can remove virtually any virus RNA within 48 hours, and that there is a significant reduction even after 24 hours,” explains Dr. Kylie Wagstaff from the Biomedicine Discovery Institute (BDI) at Monash University.
Now it is necessary to find out whether the dosage of the possible coronavirus vaccine that humans can tolerate is also effective. When and whether tests on humans are approved for “ivermectin” is still unclear. By the way: You can help with the search for a suitable coronavirus vaccine.
Latest videos on futurezone.de
– Latest videos on futurezone.de
–
show description
– .
